On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.

@article{Cai2010OntreatmentSH,
  title={On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.},
  author={Wei Cai and Qing Xie and Baoyan An and Hui Wang and Xiaqiu Zhou and Guomin Zhao and Qing Qu Guo and Ruiying Gu and Shisan S. Bao},
  journal={Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
  year={2010},
  volume={48 1},
  pages={22-6}
}
BACKGROUND Effective management of chronic hepatitis B infection is still very challenging, despite decades of clinical research. Telbivudine is one of the most frequently used antiviral drug at the current stage, but its long-term effectiveness, particularly at off-treatment, is still unclear. OBJECTIVES To assess on-treatment HBsAg kinetics in patients… CONTINUE READING